The CASP6 Knockout Jurkat Polyclonal Cells product provides a ready-to-use CRISPR/Cas9-edited polyclonal knockout cell population targeting the CASP6 gene in the Jurkat T-lymphoblast background. This polyclonal pool of CASP6-disrupted Jurkat cells is designed for investigating executioner caspase biology in a human T-cell signaling and leukemia model.
The Jurkat cell line is a widely used human T-lymphoblastoid line derived from the peripheral blood of a 14-year-old male with acute T-cell leukemia. It serves as a well-characterized model for T-cell receptor signaling, activation-induced cell death, and acute lymphoblastic leukemia pathogenesis. The parental Jurkat line retains functional death receptor pathways and downstream apoptotic machinery, making it particularly suitable for loss-of-function studies of caspases and other apoptosis regulators.
CASP6 encodes an executioner caspase that functions downstream of initiator caspases such as CASP8 and CASP9, which are activated by death receptor engagement (via TNF, FasL, TRAIL) or mitochondrial cytochrome c release mediated by CYCS and APAF1. Once proteolytically activated, CASP6 cleaves critical substrates including lamin A/C (LMNA), poly(ADP-ribose) polymerase 1 (PARP1), and inhibitor of caspase-activated DNase (ICAD), driving the biochemical and morphological hallmarks of apoptosis. CASP6 also interacts with other apoptosis regulators including CASP8, CASP10, FADD, and members of the BCL2 family, and its activity is modulated by inhibitors such as XIAP and CFLAR. Beyond apoptosis, CASP6 participates in TNF signaling, p53-mediated cell death, and the inflammasome pathway, linking it to inflammatory responses and neurodegeneration.
In Jurkat cells, the disruption of CASP6 creates a loss-of-function model for examining T-cell apoptosis, drug-induced cytotoxicity, and the interplay between death receptor and mitochondrial apoptotic pathways. Given the Jurkat line??s dependence on caspase activity for executing apoptosis in response to chemotherapeutic agents and death receptor ligands, CASP6 knockout pools allow researchers to dissect the specific contribution of this executioner caspase to cell death signaling cascades. This model is particularly relevant for studying mechanisms of resistance to apoptosis in T-cell acute lymphoblastic leukemia and for identifying targets that sensitize cancer cells to therapy.
The CASP6 Knockout Jurkat Polyclonal Cells are suitable for a range of experimental applications including apoptosis signaling studies, high-throughput cancer drug screening, neurodegeneration research, and inflammation research. Typical assays with this tool include Western blotting to monitor caspase-6 cleavage and substrate processing, caspase activity assays using fluorogenic or luminogenic substrates, flow cytometry with Annexin V/propidium iodide staining to quantify apoptotic induction, RT-qPCR to measure expression changes in downstream targets such as LMNA and PARP1, and co-immunoprecipitation to profile protein interactions with known partners like CASP8 and FADD. For additional technical details, please contact Ascent Research.
